A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
作者： A K Nowak , M J Byrne , R Williamson , G Ryan , A Segal
关键词: Progressive disease 、 Survival analysis 、 Pleural disease 、 Phases of clinical research 、 Chemotherapy 、 Gemcitabine 、 Gastroenterology 、 Internal medicine 、 Surgery 、 Pulmonary function testing 、 Mesothelioma 、 Medicine
摘要: Our previous phase II study of cisplatin and gemcitabine in malignant mesothelioma showed a 47.6% (95% CI 26.2-69.0%) response rate with symptom improvement responding patients. Here we confirm these findings multicentre setting, assess the effect this treatment on quality life pulmonary function. Fifty-three patients pleural received 100 mg m(-2) i.v. day 1 1000 days 1, 8, 15 28 cycle for maximum six cycles. Quality function were assessed at each cycle. The best achieved 52 assessable was: partial response, 17 (33%, 95% 20-46%); stable disease, 31 (60%); progressive four (8%). median time to disease progression was 6.4 months, survival from start 11.2 diagnosis 17.3 months. Vital capacity global remained all improved significantly Major toxicities haematological, limiting mean relative dose intensity 75%. This schedule is active setting. Investigation alternative scheduling needed decrease haematological toxicity increase whilst maintaining life.
uq.edu.au
nature.com参考文章(30)
R Rosell, A Sandler, M Tonato, The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer. Seminars in Oncology. ,vol. 25, pp. 27- 34 ,(1998)
B. J. M. Braakhuis, G. J. Peters, C. M. Kuiper, G. Veerman, V. W. T. Ruiz Van Haperen, A. M. Bergman, Interaction between cisplatin and gemcitabine in vitro and in vivo. Seminars in Oncology. ,vol. 22, pp. 72- 79 ,(1995)
F A Shepherd, W P Steward, R P Abratt, M R Green, G J Peters, B Nguyen, L Crino, A N Sandler, Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery. Seminars in Oncology. ,vol. 25, pp. 35- 43 ,(1998)
TNM classification of malignant tumours Published in <b>2010</b> in Chichester, West Sussex, UK ;Hoboken, NJ by Wiley-Blackwell. ,(1987) , 10.1007/978-3-642-82982-6
Jeremy P. C. Steele, Jonathan Shamash, Marie T. Evans, Nicole H. Gower, Marc D. Tischkowitz, Robin M. Rudd, Phase II Study of Vinorelbine in Patients With Malignant Pleural Mesothelioma Journal of Clinical Oncology. ,vol. 18, pp. 3912- 3917 ,(2000) , 10.1200/JCO.2000.18.23.3912
Robert A. Nagourney, John S. Link, Jonathan B. Blitzer, Cynthia Forsthoff, Steven S. Evans, Gemcitabine Plus Cisplatin Repeating Doublet Therapy in Previously Treated, Relapsed Breast Cancer Patients Journal of Clinical Oncology. ,vol. 18, pp. 2245- 2249 ,(2000) , 10.1200/JCO.2000.18.11.2245
Giuseppe De Cataldis, Annunziato Iannelli, Domenico Bilancia, Mario Belli, Bruno Massidda, Francovito Piantedosi, Giuseppe Comella, Mario De Lena, Giuseppe Frasci, Vito Lorusso, Nicola Panza, Pasquale Comella, Gianpaolo Nicolella, Andrea Bianco, Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 18, pp. 2529- 2536 ,(2000) , 10.1200/JCO.2000.18.13.2529
L Crinò, G Scagliotti, M Marangolo, F Figoli, M Clerici, F De Marinis, F Salvati, G Cruciani, L Dogliotti, F Pucci, A Paccagnella, V Adamo, G Altavilla, P Incoronato, M Trippetti, A M Mosconi, A Santucci, S Sorbolini, C Oliva, M Tonato, Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. Journal of Clinical Oncology. ,vol. 15, pp. 297- 303 ,(1997) , 10.1200/JCO.1997.15.1.297
S T Ong, N J Vogelzang, Chemotherapy in malignant pleural mesothelioma. A review. Journal of Clinical Oncology. ,vol. 14, pp. 1007- 1017 ,(1996) , 10.1200/JCO.1996.14.3.1007
J. Peto, F.E. Matthews, J.T. Hodgson, J.R. Jones, Continuing increase in mesothelioma mortality in Britain The Lancet. ,vol. 345, pp. 535- 539 ,(1995) , 10.1016/S0140-6736(95)90462-X